High-Content Screening for Cryptosporidium Drug Discovery

Methods Mol Biol. 2020:2052:303-317. doi: 10.1007/978-1-4939-9748-0_17.

Abstract

High-content screening (HCS) is a cell-based type of phenotypic screening that combines multiple simultaneous readouts with a high level of throughput. A particular benefit of this form of screening for drug discovery is the ability to perform the interrogation in a biologically relevant system. This approach has greatly advanced the field of drug discovery for cryptosporidiosis, a diarrheal disease caused by protozoan parasites of Cryptosporidium spp. These parasites are obligate intracellular parasites and cannot be cultured in vitro without the support of a host cell, limiting the options for potential assay readout. Here we describe an established 384- or 1536-well format high-content imaging (HCI) assay of Cryptosporidium-infected HCT-8 human ileocecal adenocarcinoma cells. This HCS assay is a powerful tool to assess large numbers of compounds to power drug discovery, as well as to phenotypically characterize known Cryptosporidium-active compounds.

Keywords: Anti-cryptosporidial; Cryptosporidiosis; Cryptosporidium; Drug discovery; High-content imaging; High-throughput screening; Infectious diseases; Neglected tropical diseases; Phenotypic screening.

MeSH terms

  • Antiprotozoal Agents / pharmacology*
  • Cell Line, Tumor
  • Cryptosporidium parvum / drug effects*
  • Drug Discovery / methods*
  • High-Throughput Screening Assays
  • Humans
  • Oocysts / drug effects*
  • Phenotype
  • Workflow

Substances

  • Antiprotozoal Agents